Signal Eight psychedelic candidates hold FDA breakthrough therapy designation

Summary

The Initiative counts eight psychedelic drug candidates granted FDA breakthrough therapy designation, which confers expedited review. The named programmes span psilocybin and its analogues, LSD-based compounds, MDMA, intranasal 5-MeO-DMT, methylone and a subcutaneous psilocybin prodrug from eight separate developers.